S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
From -60% Account to Doubling His Money? (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
From -60% Account to Doubling His Money? (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
From -60% Account to Doubling His Money? (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
From -60% Account to Doubling His Money? (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:EPIX

ESSA Pharma (EPIX) Competitors

$3.02
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$2.92
$3.05
50-Day Range
$2.60
$3.15
52-Week Range
$1.40
$5.38
Volume
17,242 shs
Average Volume
150,593 shs
Market Capitalization
$133.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

EPIX vs. GRTX, IXHL, AFMD, CELU, IVA, OGI, ESPR, PYXS, TRVI, and MIST

Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Galera Therapeutics (GRTX), Incannex Healthcare (IXHL), Affimed (AFMD), Celularity (CELU), Inventiva (IVA), Organigram (OGI), Esperion Therapeutics (ESPR), Pyxis Oncology (PYXS), Trevi Therapeutics (TRVI), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.

ESSA Pharma vs.

Galera Therapeutics (NASDAQ:GRTX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

ESSA Pharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$62.22 million-$2.22-1.37
ESSA PharmaN/AN/A-$35.10 million-$0.65-4.65

In the previous week, Galera Therapeutics and Galera Therapeutics both had 2 articles in the media. Galera Therapeutics' average media sentiment score of 0.51 beat ESSA Pharma's score of -0.35 indicating that Galera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galera Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ESSA Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

36.5% of Galera Therapeutics shares are owned by institutional investors. 8.6% of Galera Therapeutics shares are owned by insiders. Comparatively, 12.0% of ESSA Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ESSA Pharma received 295 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 76.16% of users gave ESSA Pharma an outperform vote while only 57.47% of users gave Galera Therapeutics an outperform vote.

CompanyUnderperformOutperform
Galera TherapeuticsOutperform Votes
50
57.47%
Underperform Votes
37
42.53%
ESSA PharmaOutperform Votes
345
76.16%
Underperform Votes
108
23.84%

Galera Therapeutics' return on equity of 0.00% beat ESSA Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Galera Therapeutics N/A N/A -119.68%
ESSA Pharma N/A -17.63% -17.32%

Galera Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 154.10%. ESSA Pharma has a consensus price target of $17.00, indicating a potential upside of 461.98%. Given ESSA Pharma's higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Galera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
ESSA Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Galera Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Summary

ESSA Pharma beats Galera Therapeutics on 8 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EPIX vs. The Competition

MetricESSA PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$133.37M$5.74B$4.54B$6.29B
Dividend YieldN/A2.55%5.90%6.51%
P/E Ratio-4.655.4694.1412.74
Price / SalesN/A332.723,515.6296.81
Price / CashN/A20.7422.5223.57
Price / Book0.804.894.735.39
Net Income-$35.10M$177.69M$116.99M$192.53M
7 Day Performance3.24%4.60%4.78%3.72%
1 Month Performance1.85%1.99%2.60%5.11%
1 Year Performance-39.86%22.98%15.52%3.00%

ESSA Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
2.0406 of 5 stars
$3.02
-0.7%
$7.75
+156.6%
+94.3%$129.58MN/A-1.3630News Coverage
Positive News
IXHL
Incannex Healthcare
0 of 5 stars
$2.05
+1.5%
N/A-69.4%$129.96M$570,000.000.003Analyst Revision
News Coverage
Positive News
Gap Up
AFMD
Affimed
2.397 of 5 stars
$0.86
+3.6%
$5.67
+561.2%
-73.2%$127.98M$43.58M-1.22197Analyst Report
Gap Down
CELU
Celularity
1.9847 of 5 stars
$0.73
+19.8%
$6.13
+744.2%
-90.6%$130.98M$17.98M0.00162Gap Up
IVA
Inventiva
2.252 of 5 stars
$3.00
+6.4%
$36.00
+1,100.0%
-56.7%$126.39M$12.83M0.00101Positive News
Gap Up
OGI
Organigram
1.4167 of 5 stars
$0.41
-6.8%
$1.67
+306.5%
-61.1%$132.01M$166.41M-10.25841
ESPR
Esperion Therapeutics
2.2335 of 5 stars
$1.40
-4.1%
$11.17
+697.6%
-76.5%$132.59M$75.47M-0.41218Analyst Revision
PYXS
Pyxis Oncology
2.4761 of 5 stars
$3.26
+4.2%
$14.00
+329.4%
+35.7%$124.66MN/A-1.0156
TRVI
Trevi Therapeutics
2.3384 of 5 stars
$2.07
-14.8%
$7.20
+247.8%
-1.6%$124.35MN/A-5.4524Gap Up
High Trading Volume
MIST
Milestone Pharmaceuticals
1.7778 of 5 stars
$4.07
+2.3%
$19.00
+366.8%
-31.4%$135.78M$5M-2.9329

Related Companies and Tools

This page (NASDAQ:EPIX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -